Cesar A. Arias, M.D. MSc, PhD., an internationally recognized infectious disease expert, has joined Houston Methodist where he will continue his NIH-funded basic, translational and clinical research on antibiotic resistance.
He will serve as Chief of the Division of Infectious Diseases as the John F. III and Ann H. Bookout Distinguished Chair and will serve as the Co-Director of the Center for Infectious Diseases Research at Houston Methodist.Arias brings to Houston Methodist extensive accomplishments in basic and translational work on antimicrobial resistance and microbial genomics to help diagnose and treat antibiotic resistant organisms. He has published more than 200 peer-reviewed articles, books and book chapters. He is currently Chair of the Gulf Coast Consortium (GCC) on Antimicrobial Resistance and serves as Editor in Chief of Antimicrobial Agents and Chemotherapy. Arias is a member of the Board of Directors of the Infectious Diseases Society of America (IDSA) and has served as member of the IDSA COVID-19 Guidelines and both the Vice Chair and Chair of IDWeek. He was inducted into the American Society for Clinical Investigation in 2015 and to the American Academy of Microbiology in 2019. Arias has also built an outstanding educational and mentoring program in antimicrobial resistance, including serving as PI of the Gulf Coast Consortium-based NIH-funded Texas Medical Center T32 Training Program in Antimicrobial Resistance.
Arias received his medical degree from Universidad El Bosque, Bogota, Colombia, his master's in clinical microbiology at the University of London and his Ph.D. in Microbial Biochemistry and Molecular Microbiology from the University of Cambridge. He was awarded a Wellcome Trust International Fellowship in 2000 to develop antimicrobial research in Colombia, before moving to Houston in 2002 for training in Internal Medicine and Infectious Diseases at UTHealth McGovern Medical School and UT MD Anderson Cancer Center. He joined the faculty at UTHealth in 2008 where he was named a professor in 2016 and The Herbert and Margaret W. DuPont Chair in Infectious Diseases in 2017.
Digital Methodology
Cancer cell type (seed) and tumor microenvironment (soil) control therapeutic antibody delivery and efficacy
Primary tumor cells (seed) and metastatic organs (soil) determine complex tumor microenvironment heterogeneities- a major cause of resistance against immunotherapeutics, including immune checkpoint inhibitors important in breast cancer treatment strategies.
Read more in Digital Methodology.
Watch
Upcoming Activities
CVD Prevention Symposium 2021
Link to Register: cvent.me/K0MyGE
Oct. 9 | 8 a.m. to 1:30 p.m.
12th Annual Myasthenia Gravis Virtual Conferences
Link to Register: cvent.me/lzWyVg
Healthcare Professionals*
Oct. 22 | 10 a.m. – 2:30 p.m.
*Continuing Education credit offered
Patient Education
Oct. 23 | 10 a.m. – 2:30 p.m.
Watch Now on Watch Houston Methodist
8th Annual Houston Methodist IBD Lectureship
Sepsis Symposium 2021: Sepsis Survivorship
14th Annual Houston Methodist Advances in Neurology Symposium
Day 1 | Day 2
Announcements
Houston Methodist, Texas A&M Health formalize agreement to fund center for health and nature
Houston Methodist and Texas A&M University Health Science Center have formalized an agreement to support the Center for Health & Nature. The agreement establishes core funding for the center, which drives research to study the impact of nature on health with evidence-based programs that complement the full continuum of health care: prevention, treatment and recovery.
As part of the agreement, Houston Methodist and Texas A&M Health will each commit $125,000 per year to support the center. The funding will be used to hire dedicated leadership to create community connections, accelerate research and foster collaborations.
It may feel intuitive that nature is good for our health, but scientific evidence still is being compiled to support the idea. The goal of the Center for Health & Nature is to substantiate the link between nature and enhanced health. The result of the center’s research will be to produce evidence-based programs that can be used alongside traditional therapies to enhance healing, prevent disease and improve recovery from illness or injury, both within the healthcare setting and as part of lifestyle intervention. These programs will impact patients with a wide range of illnesses and conditions as well as health care workers.
Although core funding is provided by Houston Methodist and Texas A&M, Texan by Nature provides conservation expertise and access to in-kind contributions as well as staff and resources that help advance the center’s mission.
Current research projects at the center include designing systems to prevent physician and nurse burnout; evaluating the effects of a virtual window on hospital patients’ health and well-being; evaluating whether virtual reality gardening and nature settings can alleviate pain and stress as an alternative to pain medications; evaluating the kinds of green space that most positively impact pedestrian health; and examining the effects of travel to natural environments on overall health and well-being.
Houston Methodist has launched four new websites:
Chen Lab Center for Immunotherapy Research
Pan Lab Cancer Immunobiolgy & Inflammation
YouLi Lin Lab Proteomics
Ming You Lab Center for Cancer Prevention
Houston Methodist Intramural Awards portal launches
Academic Affairs is pleased to introduce the Houston Methodist Intramural Awards portal. Applications for intramural programs, including the upcoming Clinical Scholars Award Program and Bridge to TRI, must be submitted through this portal. Webinars and Q&A sessions will be provided via Microsoft Teams to help investigators and administrators learn how to use the portal. One-hour webinars will provide an overview of the submission portal with time for questions. Q&A sessions will take place the week of application submissions; an Academic Affairs representative will be available to answer individual questions.
Event
Date
Time*
Microsoft Teams Details
Submission Portal Webinar #2
Nov. 9, 2021
Noon – 1 p.m.
Click here to join the meeting
Submission Portal Q&A sessions #1
Oct. 4-7, 2021
11 a.m. – noon
Click here to join the meeting
Submission Portal Q&A sessions #2
Nov. 29-30, 2021
11 a.m. – noon
Click here to join the meeting
Virtual Development Series for Academic Excellence
Are you interested in developing your professional and academic career? The Office of Academic Development is hosting a Virtual Development Series for Academic Excellence. You will learn about topics including working across generations, cognitive biases in teaching and learning, and more.
Join us every other Thursday at noon via Zoom. CME Credit Available.
Series Course Breakdown
Oct. 14
Working Across generations
Oct. 28
Storytelling Presentations
Nov. 11
Social Media to Advance Your Career
The George and Angelina Kostas Research Center for Cardiovascular Nanomedicine International Meeting
The George and Angelina Kostas Research Center for Cardiovascular Nanomedicine will host its annual international meeting Oct. 18. This virtual conference will be from 9 a.m. to 5:30 p.m.
The course is directed by John P. Cooke, MD, PhD, and Alessandro Grattoni, PhD.
This conference will foster collaborations between clinicians and research scientists from around the world who are working toward high-impact solutions that apply nanomedicine approaches to diagnose and treat cardiovascular diseases. International experts will showcase the use of emerging, novel technologies in nanomedicine and their applications for healing patients with heart disease. Presentations focus on the latest medical advances, treatments, leading-edge research, and future trends in cardiovascular disease and nanomedicine.
The featured speakers are:
- Bruna Corradetti, PhD, MSc, Houston Methodist
- Pieter Cullis, PhD, University of British Columbia/Nanomedicines Innovation Network
- Tejal Desai, PhD, University of California San Francisco
- Eduardo Marbán, MD, PhD, Cedars-Sinai Medical Center
- Joan Nichols, PhD, Houston Methodist
- Henry Pownall, PhD, Houston Methodist
- Francesca Taraballi, PhD, Houston Methodist
- Omid Veiseh, PhD, Rice University
Praying for each other
It has been a little over a year since the launch of the Prayer Connect Team at Houston Methodist Hospital. Every week, an email has been sent out to this community with requests to pray over. In that time, nearly 160 Methodist employees have committed to pray for more than 500 requests from our colleagues and community.
We believe that staying connected is vital to our wellbeing, so please consider joining the chaplains in this initiative. If you would like to join us in praying for the requests of our employees and community, please reply to this email or contact Michela deTranaltes, Project Specialist for Grace Ministries at mdetranaltes@houstonmethodist.org, so we can add you to our confidential online community.
If you would like to submit a prayer, either text PRAYER to 45991 or email us at HMHPrayerRequest@houstonmethodist.org.
Hang Ten: Employee Support Group
Hang Ten provides a safe and confidential environment for mutual support. A chaplain will facilitate the group and introduce life tools such as mindfulness, intentionality and reframing.
Each session will stand alone, so feel free to log on any week for as long as your time permits. We meet every Tuesday from 12-1 pm. The recurring meeting link is below:
Join WebEx meeting
Meeting number (access code): 130 671 0123
Meeting password: jFV7JBsmK72
Tap to join from a mobile device (attendees only)
404-397-1503,,1306710123## US Toll
877-209-1359,,1306710123## US TF
Join by phone
404-397-1503 US Toll
877-209-1359 US TF
Accolades
The City of Houston recently recognized Faisal Masud, MD, Director for Critical Care, for his leadership during the coronavirus pandemic.
Maen Abdelrahim, MD, recently received $1.46 million from Genentech in clinical product support for Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria: A Feasibility Study.
Robert Phillips, M.D., Ph.D., recently served as a panelist on Webinar: Hospital Emergency Preparedness: Building Resiliency Into Crisis Management Plans. The webinar was part of Healthcare of Tomorrow, a virtual event series from U.S. News & World.
The Academic Office of Clinical Trials has consented more than 1,400 people for convalescent plasma donation.
NIH News
NIH loan repayment programs accepting applications
The NIH Loan Repayment Program (LRP) application cycle closes on Nov. 18. Participants in the NIH LRPs can receive up to $100,000 of qualified educational debt repayment with a two-year contract. To qualify as an LRP, the applicant:
- is employed to conduct research for an average of at least 20 hours a week per quarter at your institution;
- will not receive any salary or research funding support from a for-profit source during their LRP contract period, if awarded;
- has protected research time for the length of the LRP award;
- has research that is not prohibited by Federal Law; and
- is a U.S. citizen, national, or permanent resident
- an active NIH Commons ID,
- the BO role assigned to your Commons account, and
- an up-to-date password.
COVID-19 Resources
Houston Methodist provides a variety of tools to facilitate collaborative research projects related to coronavirus. The following resources are available at https://www.tmc.edu/coronavirus-updates/
- Elsevier Coronavirus Research Hub Curated COVID-19 Funding Opportunities
- National Institutes of Health Coronavirus (COVID-19) Resources
- PURE Coronavirus Portal for Research Collaboration
- Read about our COVID-19 research on the Methodology COVID-19 News page. Read our seven-step process as told to the Harvard Business Review that can help employers decide about employee-mandated COVID-19 vaccinations
In the Media
Houston Methodist patient Kathleen Bernard shared her experience with post-COVID symptoms in a Houston Chronicle COVID-19 story entitled “The Unseen Damage of COVID-19,” which was published Sept. 5. Bernard is a patient of Houston Methodist’s Kenneth Podell, PhD, who worked with Bernard and other patients suffering from what is referred to as “long-haulers” syndrome. Researchers continue to investigate the root causes but suspect inflammation as the main culprit. “Just because we can’t see it, doesn’t mean it does not exist,” Podell says in the story, which can be read here.
Houston Methodist Senior Chaplain Brian Gowan spoke with Fox 26 news reporter Maria Salazar on stories of Texas Medical Center chaplains offering comfort during the ongoing COVID-19 pandemic. Gowan talked about the challenges of offering emotional healing and spiritual support during times that are hard on everyone involved.
Howard J. Huang, MD, was recently interviewed by The Guardian as an expert source for a story about the potential for monoclonal antibodies to be used as pre-exposure prophylaxis (PrEP) against SARS-CoV-2 among immunocompromised individuals. This is a new treatment approach different from the currently FDA-approved post-exposure prophylaxis (PEP) in which individuals receive an injection after being exposed to a person infected with Covid-19.
Rahul Pandit, MD, associate professor of clinical ophthalmology with the Blanton Eye Institute at Houston Methodist, provided comments on a story looking at pink eye (conjunctivitis) as a symptom of COVID-19. The story is for TheHealthy.com and was also picked up by MSN.com.
LaTesha Montgomery, MHA, RN, was featured in “AI: Beyond the Buzz,” where she discussed how Houston Methodist was able to quickly deploy technology like Syllable and Care.AI during the pandemic. She highlights the Center for Innovation and DIOP for having a strong infrastructure in place to review and vet new AI technologies.
Nicholas Desai, DPM, was interviewed for a story in the Financial Times titled, “The next Big Tech battle: Amazon’s bet on healthcare begins to take shape.” He discussed how the AWS OR technology works as well as how the voice tech in the exam rooms functions as a “second set of ears” for physicians. Becker’s Hospital Review summarized the FT article into seven key takeaways. See “Houston Methodist, Amazon piloting voice assistants in the operating exam rooms.”
The Houston Chronicle recently featured a front-page article on some COVID patients/families demanding the use of ivermectin, a drug approved to treat some parasitic infections, not coronavirus. Josh Septimus, MD, and Faisal Masud, MD, are featured, and they spoke of the hostility they and their staff are seeing from some patients.
Fecal transplants have long been used to treat C. difficile colitis (C. diff). Eamonn Quigley, MD, recently spoke with Time magazine on the benefits of fecal transplants for irritable bowel disease. He is one of several experts included in the Time article, which was also picked up by Yahoo.com and MSN.com.
Mas Takashima, MD, FACS, was a co-principal investigator on a clinical trial focused on a new treatment for chronic rhinitis that is proving to be a more effective alternative to medications. A research paper recently published in OTO Open, and the company issued a press release, which was picked up by various sites including NS Medical Devices and Biospace.
News releases were issued recently on a pair of peer-reviewed Covid-19 studies from Edward Graviss, PhD, and Sonia Villapol, PhD. The studies were originally described in a joint news release posted on our Houston Methodist newsroom.
The studies then were split the releases into two standalone stories.
Graviss and team’s cohort study, published in PLoS One, looked at Covid risk factors for severe disease in young adults in the 18-29 age range. You can find the release posted here on Graviss and team’s retrospective study. Villapol’s systematic review paper, which was released earlier this year as a preprint in medRxiv, has now been published in Nature’s Scientific Reports and identifies 50-plus lingering effects that can be experienced weeks to months after recovering from Covid. You can find the release posted here for Villapol and team’s meta-analysis.
The stories were published in Eurasia Review, Global Health Newswire, SciTech Daily and the NewsBreak app.
Here’s a sampling of some recent COVID media coverage.
MSN.com – Do You Need a Covid-19 Booster Shot?
Houston Chronicle:
How can you tell the difference between COVID and a cold?
Number of reported COVID cases among Texas students nearly triples in a week
Business Insider – People taking dangerous doses of ivermectin for COVID-19 say they're pooping out worms, but it's probably vegetables or mucus
Mandating COVID vaccination increases freedom, despite claims to the contrary | COMMENTARY - Baltimore Sun
Job Postings
We have job openings in the Academic Institute. Please visit the links below to find one that interests you.
- Senior Science Editor
There are many other jobs open in the Academic Institute. Click here to see if there’s one that interests you, or if you know someone who might be interested.
Policy Reminders from the Business Practices Office
BP in Practice is an educational reminder designed to raise awareness regarding Business Practices hot topics, relevant laws and policies & procedures. Find archives of BP in Practice here.
- The October 2021 issue of BP in Practice focuses on fundraisers and Halloween activities.
- Use these links to access PDFs of System Policies BP19 and HR21. If you have questions, contact the BP Ethics Line at 800.500.0333 or visit https://tmhs.alertline.com/gcs/welcome
Publications
A brief diagnostic screen for cluster headache: Creation and initial validation of the Erwin Test for Cluster Headache
Randika Parakramaweera, Randolph W. Evans, Larry I. Schor, Stuart M. Pearson, Rebecca Martinez, Jacob S. Cammarata, Amisha J. Amin, Seung Hee Yoo, Wei Zhang, Yuanqing Yan, Mark J. Burish. 10.1177/03331024211018138
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy
Charles C. Wykoff, Philip J. Rosenfeld, Nadia K. Waheed, Rishi P. Singh, Nick Ronca, Jason S. Slakter, Giovanni Staurenghi, Jordi Monés, Caroline R. Baumal, Namrata Saroj, Ravi Metlapally, Ramiro Ribeiro. 10.1016/j.ophtha.2021.02.025
Assessing Patient Needs During Natural Disasters: Mixed Methods Analysis of Portal Messages Sent During Hurricane Harvey
Juha Baek, Bridget Simon-Friedt, Adriana Lopez, Jacob M Kolman, Juan Nicolas, Stephen L Jones, Robert A Phillips, Terri Menser. 10.2196/31264
Attributable mortality of acute respiratory distress syndrome: A systematic review, meta-analysis and survival analysis using targeted minimum loss-based estimation
Lisa K. Torres, Katherine L. Hoffman, Clara Oromendia, Ivan Diaz, John S. Harrington, Edward J. Schenck, David R. Price, Luis Gomez-Escobar, Angelica Higuera, Mayra Pinilla Vera, Rebecca M. Baron, Laura E. Fredenburgh, Jin Won Huh, Augustine M.K. Choi, Ilias I. Siempos. 10.1136/thoraxjnl-2020-215950
Biopsychosocial intersections of social/affective touch and psychiatry: Implications of ‘touch hunger’ during COVID-19
Debanjan Banerjee, Velmarini Vasquez, Marisin Pecchio, Muralidhar L. Hegde, Rao Ks Jagannatha, TS Sathyanarayana Rao. 10.1177/0020764021997485
If you have a featured publication, for example on a journal cover, please let us know so we can include it in our next issue.
Funding Opportunities
Bridge to Translational Research Initiative (B2TRI)
The Houston Methodist Academic Institute (HMAI) is pleased to reissue the Bridge to Translational Research Initiative (B2TRI) Request for Applications, which provides funding for promising and clinically relevant research (molecular, cellular or early pre-clinical research) to advance for TRI funding consideration. Typically, B2TRI eligible projects are not yet positioned for development under Good Laboratory Practices (GLP) conditions or Good Manufacturing Practices (GMP), or for clinical trials.
Key Dates
Applications Due: Oct. 8, 2021, at Noon CST
Applications Reviewed: October - November 2021
Awards Announced: December 2021
Estimated Funding Start Date: Jan. 1, 2022
Academic Affairs is pleased to introduce the Houston Methodist Intramural Awards portal. Applications for the Bridge to Translational Research Initiative must be submitted through this portal. More details are provided in the Submission Guidelines section of the attached RFA. Webinar and Q&A dates are listed below. All sessions will be held via Microsoft Teams. Please reach out to Academic Affairs for meeting details.
Submission Portal Webinar: Sept. 16, 2021, Noon – 1 pm CST
Submission Portal Q&A Sessions: Oct. 4-7, 2021, 11 am – Noon CST
Eligibility
Any Houston Methodist-employed faculty with a primary HMAI academic appointment is eligible to apply as a Principal Investigator (PI).
Proposed projects must be based on Houston Methodist Inventions. Before applying to the B2TRI program, applicants must consult with the Houston Methodist Office of Technology Transfer (OTT), for further details regarding eligibility. Sign off from an OTT representative is a required application component.
To help inform the study design as a strategic approach to translation, interested applicants are required to meet with the Office of Regulatory Affairs and Translational Management (Christina Talley - ctalley@houstonmethodist.org). Sign off from an ORATM representative is a required application component.
Funding Information
Applicants may propose a project funding period of up to six months and a budget of up to $50,000 in total costs, direct costs only. Salary support is not permitted. Subcontracts are not eligible for B2TRI funds. No cost sharing or matching is available or required.
The number of awards given under this funding opportunity is subject to the quality of applications, the availability of funds, and program funding priorities. For selected applications, receipt of these funds is contingent upon the acknowledgement and acceptance of the Terms of Award Agreement, which is described in the Terms of Agreement with Inventors section of the RFA.
Summary of Submission Requirements
Please review the attached RFA for full details.
Project Summary/ Abstract
- Application Questions
- List of References Cited
- Budget (budget template provided)
- Budget Justification
- Biosketch
- B2TRI Collaborating Offices Sign-off Form
- Supervisor Support Letter (if applicable)
Golfers Against Cancer Request for Applications
Key Dates
Submission Portal Q&A sessions: Oct. 13-15, 2021, 11 a.m. – Noon CST
Applications Due: Oct. 15, 2021, at Noon CST
Applications Reviewed: October - November 2021
Limited Submission Selection: November 2021
Golfers Against Cancer (GAC) announces the reissuance of their Request for Applications (RFA) to support cancer research in all areas of cancer and for proposals meeting the following criteria:
- Research aimed at finding a cure for cancer.
- Proposed research is innovative with a high potential for a medical breakthrough.
- Results are not limited to only one type of cancer and have the potential to impact large numbers of cancer patients.
- Successful applications write in lay terms, as members of the public comprise the review committee.
- Applicants must use the provided application form. Narratives must fit into the space allocated for each question/inquiry. Do not expand boxes or reduce font size to accommodate lengthy explanations. The application must remain a legible, two-page document.
- Please include a brief description of how the results and data from your research project will be shared with other institutions in the Texas Medical Center and abroad.
- Save the application as a two-page PDF document (Funding Application and Budget tabs only) and upload it to Houston Methodist Intramural Awards portal.
Houston Methodist Academic Institute President’s Awards
Call for Nominations
The Houston Methodist Academic Institute (HMAI) is pleased to announce the following six award opportunities. All awards require nomination by the Department Chair, Center of Excellence Director, or Vice-Chair of Research. Please see the attached RFA for full details and eligibility information.
KEY DATES
Nominations Due: October 27, 2021, at Noon CST
Awards Announced: November HMAI Town Hall
Academic Affairs is pleased to introduce the Houston Methodist Intramural Awards portal. Applications for the President's Awards must be submitted through this portal. More details are provided in the Submission Guidelines section of the attached RFA. Webinar and Q&A dates are listed below. All sessions will be held via Microsoft Teams. Please reach out to Academic Affairs for meeting details.
Submission Portal Webinar: October 13, 2021, Noon – 1:00 pm CST
Submission Portal Q&A Sessions: October 25-26, 2021, 11:00 am – Noon CST
NIH COMPETITIVENESS AWARD INITIATIVE
Eligible nominees must have applied for an NIH grant, R01 or equivalent, that was not funded but scored within 10% above the pay line. Award recipients will receive up to $50,000 toward activities that support grant resubmission with the aim to achieve funding success. Applicants must submit 1) letter of nomination from their Department Chair, Center of Excellence Director, or Vice-Chair of Research, 2) grant summary statement, 3) copy of the grant, 4) proposed NIH resubmission strategy, and 5) proposed HM budget to support research activities for NIH resubmission.
CAREER CORNERSTONE AWARD
Eligible nominees will have received their first career NIH R01 grant as a Principal Investigator (PI). PIs will receive the equivalent of 50% of the budgeted indirect costs as a discretionary fund for use toward eligible academic activities (excluding capital equipment purchases). For grants with more than one PI, the award amount will be based on the awarded NIH budget for the nominated PI. The discretionary fund will be active for the duration of the original NIH project period. Applicants must submit 1) a nomination letter from their Department Chair, Center of Excellence Director, or Vice-Chair of Research, 2) NIH grant award notice, 3) the grant budget, and 4) a copy of the grant.
AWARD FOR EXCELLENCE IN PEER-REVIEWED PUBLICATION
Eligible nominees include Houston Methodist-employed junior faculty that recently published a manuscript in a high impact journal, such as New England Journal of Medicine, Journal of the American Medical Association, Lancet, Nature, Cell, Science, or their specialized sister journals. Junior faculty members listed as first or corresponding author can receive up to $5,000 in discretionary funds toward eligible academic activities. Applicants must submit 1) a nomination letter that includes a brief lay summary describing the significance and impact of the work and journal impact factor, and 2) a PDF of the manuscript.
AWARD FOR EXCELLENCE IN TRANSFORMATIONAL RESEARCH
Eligible nominees with recent transformational academic achievements, such as peer-reviewed grant awards with groundbreaking conceptual advances in translational research that strengthen the reputation of Houston Methodist, are eligible for this award. Faculty members listed as PI can receive up to $25,000 in discretionary funds toward eligible academic activities. Applicants must submit a nomination letter that includes a brief lay summary describing the significance and impact of the work. For published achievements, nominees should also submit a PDF of the grant and notice of award.
AWARD FOR EXCELLENCE IN RESEARCH
Eligible nominees include Houston Methodist-employed faculty members with recent outstanding academic achievements that show potential to significantly impact clinical translation or scientific innovation. Examples include, but are not limited to, funded U01 and R01 awards receiving a high impact score and advance new frontiers in research or bridge a critical gap between basic research and clinical applications. Other examples include licensing agreements and sponsored research agreements which bring technological advances and products into the market and support Houston Methodist technologies for commercialization. Recipients will receive up to $10,000 in discretionary funds for his/her use toward eligible academic activities. Applicants must submit a nomination letter that includes a brief lay summary describing the significance and impact of the work. For achievements that were published, nominees should also submit a PDF of grant and notice of award.
AWARD FOR EXCELLENCE IN EDUCATION
Eligible nominees include Houston Methodist-employed faculty members who have demonstrated an ongoing commitment and excellence in teaching, supervision, mentoring, innovation in trainee education or related instructional activities. Nominees will be evaluated and selected for their stellar and enduring contributions to high quality clinical and translational education that advances the practice of medicine at Houston Methodist. The award will be commensurate with the level of excellence and is at the discretion of the HMAI Executive Leadership. Applicants must submit a nomination letter that includes a narrative explaining the specific achievement in education.
Please Note: All awards are chosen by the HMAI Executive Committee; not all categories are awarded at every Town Hall Meeting.
Applications for all award opportunities must submitted be via the Houston Methodist Intramural Awards portal (https://intramural-awards.houstonmethodist.org/) by October 27, 2021, at noon (CST). Please see the provided Applicant Guide document for additional details. A webinar and Q&A sessions will be held to help familiarize nominees and administrators with the submission portal. Dates are provided in the Key Dates section of this RFA.
Link to award opportunity details page: https://intramural-awards.houstonmethodist.org/#competitionDetail/1853158
Doris Duke Charitable Foundation (DDCF) Clinical Scientist Development Award
2022 Request for Applications
Key Dates
Pre-proposal applications deadline November 12, 2021, 3 pm ET
Invitation to submit a full proposal January 14, 2022
Full proposal deadline March 11, 2022, 3 pm ET
Notice of Award End of May 2022
Award Start Date July 1, 2022
Award Overview
The purpose of the Doris Duke Clinical Scientist Development Award (CSDA) is to provide support to physician scientists at the Assistant Professor rank to: 1) conduct an outstanding clinical research project with high significance and potential to improve human health, 2) enable research time protection to ease the tension between research and clinical responsibilities, and 3) facilitate development of strong mentorship relations in a supportive institutional environment. Ultimately, the CSDA program aims to enable physician scientists’ achievement of independent and successful research careers.
Eligibility
To be eligible for this award, applicants must:
- Have received an MD, DO, or foreign equivalent degree from an accredited institution.
- Have a valid, active US medical license at the time of application, but do not have to be US citizens.
- Work at a US academic institution that grants doctoral degrees and is able to receive an award as an organization with 501(c)(3) Internal Revenue Service status. Please see the information on page 4 of the RFA and consult with your institutional grants office.
- Have a full-time faculty appointment at the Assistant Professor rank.
- Have been appointed to their first post-training, full-time Assistant Professor faculty position between December 1, 2017, and December 1, 2020 (i.e., have been at the appointment no more than 4 years but at least 1 year). Exceptions to the four-year requirement will be considered on a case-by-case basis.
- Not have served as the principal investigator, or one of multiple-principal investigators, of an extramural, multi-year (term >12 months) research grant, cooperative agreement, or contract with annual direct funding in the amount of $225,000 or higher with a start date prior to and inclusive of July 1, 2022. The CSDA is not for researchers who have already attained this level of funding, even if the researcher substituted for the original principal investigator of the grant. National Institutes of Health (NIH) K-series career development awards and startup packages are excluded from this requirement.
- Not have applied for a single or multiple-principal investigator NIH R01 research grant or equivalent as principal investigator that has a start date prior to and inclusive of July 1, 2022. This includes but is not limited to: research projects that are part of a P01 program project, P50 center grant or a U01 cooperative agreement, DP1, DP2, R37, and VA Merit grants.
- Not be in a graduate degree program at the time of the award. All education and training toward advanced degrees must be completed by the award start date, July 1, 2022.
- Be guaranteed a minimum overall research time protection of 75% of full-time professional effort by the institution where the applicant has an appointment in the event an award is made.
Clinical Scholar Awards Request for Applications
The reissuance of the Clinical Scholar Awards Request for Applications (RFA) has been announced. Academic Affairs solicits nominations of exceptionally talented individuals who are educated and trained in clinical practice and seek support for translational research, clinical trials, or education. The Clinical Scholar offers three funding tracks: The Clinician Scientist Award requires awardees to dedicate 50% of their time to laboratory research and 50% of their time to clinical practice. The Clinician Trialist Award requires awardees to devote 20% of their time to clinical research (e.g., clinical trials, patient-based research, or outcomes research) and 80% of their time to clinical practice. The Clinician Educator Award requires awardees to commit 20% of their time to educational activities (e.g., educational effectiveness research or curriculum design and implementation studies) and 80% of their time to clinical practice.
Key Dates
Applications Due: Dec. 10, 2021, at Noon CST
Applications Reviewed: December 2021 - January 2022
Awards Announced: February 2022
Academic Affairs is pleased to introduce the Houston Methodist Intramural Awards portal. Applications for the Clinical Scholar Awards Program must be submitted through this portal. More details are provided in the Submission Guidelines section of this RFA. Webinar and Q&A dates are listed below. All sessions will be held via Microsoft Teams. Please reach out to Academic Affairs for meeting details.
Submission Portal Webinar: Nov. 9, 2021, Noon – 1:00 pm CST
Submission Portal Q&A sessions: Dec. 7-9, 2021, 11:00 am – Noon CST
Funding Opportunity Overview
Houston Methodist recognizes the distinctive and critical role that clinician scientists, clinician trialists, and clinician educators play in advancing the academic mission of the system. These faculty advance our mission by:
1) Performing clinical and translational research to advance medicine and health;
2) Driving innovation and translation by conducting clinical trials; and
3) Educating the next generation of innovators and health care providers.
The goal of this funding mechanism is to recruit or retain and develop clinical faculty possessing a rare blend of talent, ambition, and devotion to doing research, conducting clinical trials, and/or to educating trainees. Houston Methodist department and Centers of Excellence chairs may nominate candidates with outstanding records of accomplishments and commitment to pursuing careers in alignment with at least one of the academic pillars of the Houston Methodist Vision for the Second Century (Clinical Research; Innovative Education; Restorative Medicine; Outcomes Research; and Precision Medicine).
Eligibility
General eligibility requirements that apply to all Clinical Scholar award types:
- Departments with less than 100 faculty members may nominate up to two candidates total per RFA cycle.
- Departments with more than 100 faculty members may nominate up to four candidates total per RFA cycle.
- The candidate must hold an MD, MD/PhD, or equivalent degree and be an active Houston Methodist clinician at the time of the award start date. Priority will be given to candidates in early career stages.
- The candidate must possess a track record of commitment to and excellence in translational research, clinical research, or education, as part of his or her graduate and post-graduate endeavors.
- Candidates must commit to pursuing research or education that aligns with at least one of the HMAI strategic areas of excellence.
- Preference is given to candidates who are not currently employed with Houston Methodist but are being actively recruited. Funded awardees must begin employment no later than the start of the funding period. Exceptions may be made on a case-by-case basis.
- Research and education activities should take place primarily at Houston Methodist facilities and those of its affiliates for the duration of the funding period.
- Clinician Scientist Award: A full 50% time commitment is required, and the supporting budget from HMAI will not exceed $250,000 per year. This award may be renewed for a second, two-year term for individuals demonstrating significant progress and potential in sustaining an independent, sponsored research program.
- Clinician Trialist Award: A full 20% time commitment is required, and the supporting budget from HMAI will not exceed $100,000 per year. This award will not be eligible for renewal following the three-year term.
- Clinician Educator Award: A full 20% time commitment is required, and the supporting budget from HMAI will not exceed $100,000 per year. This award will not be eligible for renewal following the three-year term.
- Project Summary/ Abstract
- Two Letters of Support from Nominators
- Biosketch
- Statement of Work
- Career Development Plan
- List of References Cited
- Budget
- Budget Justification
- Letters of Recommendation (minimum of three required)
Browse previous issues
Contact us at news@houstonmethodist.org
Subscribe to this internal e-newsletter here.
Houston Methodist Academic Institute
6670 Bertner Avenue, Houston, TX 77030
Copyright © 2021 Houston Methodist Academic Institute, All rights reserved.